Zhaoyang Zhu

Jul 16, 2024 | molecular-cancer.biomedcentral.com | Zhaoyang Zhu |Yigang Jin |Jing Zhou |fei chen |Minjie Chen |Zhaofeng Gao | +5 more

Currently, PD1/PD-L1 inhibitors have become an important class of immunotherapy in the treatment of ccRCC. Their clinical efficacy has been validated in multiple clinical trials. In this section, we will summarize the main clinical trial data of PD1/PD-L1 inhibitors in the treatment of ccRCC, including the trial results of drugs such as Nivolumab and Pembrolizumab. We will explore the efficacy of PD1/PD-L1 inhibitors, common resistance mechanisms, and strategies to address resistance.